RU2014115647A - Способ лечения атрофической возрастной макулярной дегенерации - Google Patents
Способ лечения атрофической возрастной макулярной дегенерации Download PDFInfo
- Publication number
- RU2014115647A RU2014115647A RU2014115647/15A RU2014115647A RU2014115647A RU 2014115647 A RU2014115647 A RU 2014115647A RU 2014115647/15 A RU2014115647/15 A RU 2014115647/15A RU 2014115647 A RU2014115647 A RU 2014115647A RU 2014115647 A RU2014115647 A RU 2014115647A
- Authority
- RU
- Russia
- Prior art keywords
- hyaluronic acid
- delivery system
- drug delivery
- cross
- linked
- Prior art date
Links
- 206010064930 age-related macular degeneration Diseases 0.000 title 1
- 208000002780 macular degeneration Diseases 0.000 title 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract 18
- 229920002674 hyaluronan Polymers 0.000 claims abstract 18
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract 18
- 238000012377 drug delivery Methods 0.000 claims abstract 12
- 229960000397 bevacizumab Drugs 0.000 claims abstract 6
- 229920000642 polymer Polymers 0.000 claims abstract 6
- 208000011325 dry age related macular degeneration Diseases 0.000 claims abstract 2
- 238000002347 injection Methods 0.000 claims abstract 2
- 239000007924 injection Substances 0.000 claims abstract 2
- 239000000203 mixture Substances 0.000 claims abstract 2
- 238000013268 sustained release Methods 0.000 claims abstract 2
- 239000012730 sustained-release form Substances 0.000 claims abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
1. Биосовместимая система доставки лекарственного средства с замедленным высвобождением для инъецирования в стекловидную полость глаза пациента с сухой возрастной дегенерацией желтого пятна (ВДЖП) для лечения сухой ВДЖП, содержащая от приблизительно 5 мкг до приблизительно 20 мкг бевацизумаба и носитель из полимерной гиалуроновой кислоты, ассоциированный с бевацизумабом, и высвобождающая от приблизительно 14 нг до приблизительно 120 нг бевацизумаба в течение периода 24 часов в течение периода времени от трех месяцев до шести месяцев.2. Система доставки лекарственного средства по п. 1, где вязкость носителя из полимерной гиалуроновой кислоты составляет от приблизительно 130000 сП до приблизительно 300000 сП при скорости сдвига приблизительно 0,1/секунду при приблизительно 25°C.3. Система доставки лекарственного средства по п. 1, где полимерная гиалуроновая кислота представляет собой поперечно сшитую гиалуроновую кислоту.4. Система доставки лекарственного средства по п. 1, где полимерная гиалуроновая кислота представляет собой поперечно несшитую гиалуроновую кислоту.5. Система доставки лекарственного средства по п. 1, где полимерная гиалуроновая кислота представляет собой смесь поперечно сшитой и поперечно несшитой гиалуроновой кислоты.6. Система доставки лекарственного средства по п. 1, где где полимерная гиалуроновая кислота обладает молекулярной массой от приблизительно 1 миллиона Да до приблизительно 2 миллионов Да.
Claims (6)
1. Биосовместимая система доставки лекарственного средства с замедленным высвобождением для инъецирования в стекловидную полость глаза пациента с сухой возрастной дегенерацией желтого пятна (ВДЖП) для лечения сухой ВДЖП, содержащая от приблизительно 5 мкг до приблизительно 20 мкг бевацизумаба и носитель из полимерной гиалуроновой кислоты, ассоциированный с бевацизумабом, и высвобождающая от приблизительно 14 нг до приблизительно 120 нг бевацизумаба в течение периода 24 часов в течение периода времени от трех месяцев до шести месяцев.
2. Система доставки лекарственного средства по п. 1, где вязкость носителя из полимерной гиалуроновой кислоты составляет от приблизительно 130000 сП до приблизительно 300000 сП при скорости сдвига приблизительно 0,1/секунду при приблизительно 25°C.
3. Система доставки лекарственного средства по п. 1, где полимерная гиалуроновая кислота представляет собой поперечно сшитую гиалуроновую кислоту.
4. Система доставки лекарственного средства по п. 1, где полимерная гиалуроновая кислота представляет собой поперечно несшитую гиалуроновую кислоту.
5. Система доставки лекарственного средства по п. 1, где полимерная гиалуроновая кислота представляет собой смесь поперечно сшитой и поперечно несшитой гиалуроновой кислоты.
6. Система доставки лекарственного средства по п. 1, где где полимерная гиалуроновая кислота обладает молекулярной массой от приблизительно 1 миллиона Да до приблизительно 2 миллионов Да.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/176,238 US8821870B2 (en) | 2008-07-18 | 2008-07-18 | Method for treating atrophic age related macular degeneration |
| US12/176,238 | 2008-07-18 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2011105409/15A Division RU2521338C9 (ru) | 2008-07-18 | 2009-07-13 | Способ лечения атрофической возрастной макулярной дегенерации |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018133133A Division RU2018133133A (ru) | 2008-07-18 | 2018-09-19 | Способ лечения атрофической возрастной макулярной дегенерации |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2014115647A true RU2014115647A (ru) | 2015-10-27 |
| RU2668371C2 RU2668371C2 (ru) | 2018-09-28 |
Family
ID=41530477
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2011105409/15A RU2521338C9 (ru) | 2008-07-18 | 2009-07-13 | Способ лечения атрофической возрастной макулярной дегенерации |
| RU2014115647A RU2668371C2 (ru) | 2008-07-18 | 2009-07-13 | Способ лечения атрофической возрастной макулярной дегенерации |
| RU2018133133A RU2018133133A (ru) | 2008-07-18 | 2018-09-19 | Способ лечения атрофической возрастной макулярной дегенерации |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2011105409/15A RU2521338C9 (ru) | 2008-07-18 | 2009-07-13 | Способ лечения атрофической возрастной макулярной дегенерации |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018133133A RU2018133133A (ru) | 2008-07-18 | 2018-09-19 | Способ лечения атрофической возрастной макулярной дегенерации |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US8821870B2 (ru) |
| EP (4) | EP3524270B1 (ru) |
| JP (3) | JP2011528656A (ru) |
| KR (1) | KR20110047196A (ru) |
| CN (2) | CN107412778A (ru) |
| AU (1) | AU2009271168B2 (ru) |
| BR (1) | BRPI0915981A2 (ru) |
| CA (1) | CA2731270C (ru) |
| ES (3) | ES2720882T3 (ru) |
| RU (3) | RU2521338C9 (ru) |
| WO (1) | WO2010009034A2 (ru) |
Families Citing this family (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090148527A1 (en) * | 2007-12-07 | 2009-06-11 | Robinson Michael R | Intraocular formulation |
| US20070202186A1 (en) * | 2006-02-22 | 2007-08-30 | Iscience Interventional Corporation | Apparatus and formulations for suprachoroidal drug delivery |
| US8197435B2 (en) | 2006-05-02 | 2012-06-12 | Emory University | Methods and devices for drug delivery to ocular tissue using microneedle |
| US8039010B2 (en) | 2006-11-03 | 2011-10-18 | Allergan, Inc. | Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier |
| US8821870B2 (en) * | 2008-07-18 | 2014-09-02 | Allergan, Inc. | Method for treating atrophic age related macular degeneration |
| US8623395B2 (en) | 2010-01-29 | 2014-01-07 | Forsight Vision4, Inc. | Implantable therapeutic device |
| US8399006B2 (en) | 2009-01-29 | 2013-03-19 | Forsight Vision4, Inc. | Posterior segment drug delivery |
| CA2776472A1 (en) * | 2009-10-01 | 2011-04-07 | Evonik Degussa Corporation | Microparticle compositions and methods for treating age-related macular degeneration |
| CN102711756A (zh) * | 2010-01-14 | 2012-10-03 | 株式会社三和化学研究所 | 用于预防或治疗伴有眼内血管生成及/或眼内血管通透性增高的疾病的药物 |
| EP2525793B1 (en) * | 2010-01-21 | 2018-09-05 | Allergan, Inc. | Alpha-2 adrenergic agonist having long duration of intraocular pressure-lowering effect |
| US20130210876A1 (en) * | 2010-01-21 | 2013-08-15 | Allergan, Inc | Alpha-2 adrenergic agonist having long duration of intraocular pressure-lowering effect |
| US10166142B2 (en) | 2010-01-29 | 2019-01-01 | Forsight Vision4, Inc. | Small molecule delivery with implantable therapeutic device |
| EP2563359A1 (en) | 2010-04-30 | 2013-03-06 | Allergan, Inc. | Novel treatment for age related macular degeneration and ocular ischemic disease associated with complement activation by targeting 5-lipoxygenase |
| EP2600930B1 (en) | 2010-08-05 | 2021-02-17 | ForSight Vision4, Inc. | Injector apparatus for drug delivery |
| LT2600812T (lt) | 2010-08-05 | 2021-11-10 | Forsight Vision4, Inc. | Aparatas, skirtas akiai gydyti |
| AU2011285548B2 (en) | 2010-08-05 | 2014-02-06 | Forsight Vision4, Inc. | Combined drug delivery methods and apparatus |
| MX2013001870A (es) | 2010-08-17 | 2013-07-03 | Ohr Pharmaceutical Inc | Formulaciones oftalmicas de escualamina. |
| US20120271272A1 (en) | 2010-10-15 | 2012-10-25 | Iscience Interventional Corporation | Device for ocular access |
| CA2818612C (en) * | 2010-11-19 | 2020-12-29 | Forsight Vision4, Inc. | Therapeutic agent formulations for implanted devices |
| WO2012105610A1 (ja) * | 2011-02-02 | 2012-08-09 | 公立大学法人名古屋市立大学 | 眼内血管新生及び／又は眼内血管透過性亢進を伴う疾患の予防又は治療のための医薬 |
| US20120276186A1 (en) | 2011-04-29 | 2012-11-01 | Ghebremeskel Alazar N | Sustained release latanoprost implant |
| BR112013031685B1 (pt) * | 2011-06-10 | 2021-04-06 | Icon Bioscience, Inc. | Formulações de liberação prolongada para entrega de proteínas ao olho e métodos de preparar as mesmas |
| US9592251B2 (en) | 2011-06-16 | 2017-03-14 | The Hong Kong University Of Science And Technology | Multi-vinylsulfone containing molecule |
| US10398592B2 (en) | 2011-06-28 | 2019-09-03 | Forsight Vision4, Inc. | Diagnostic methods and apparatus |
| RU2014105495A (ru) * | 2011-07-19 | 2015-08-27 | Уилфред ДЖЕФФРИС | Способы диагностики и лечения болезни альцгеймера |
| HUE054578T2 (hu) | 2011-09-16 | 2021-09-28 | Forsight Vision4 Inc | Fluidumcserélõ berendezés |
| WO2013074840A1 (en) * | 2011-11-15 | 2013-05-23 | Allergan, Inc. | Treatment of dry age related macular degeneration |
| JP6317748B2 (ja) | 2012-09-27 | 2018-04-25 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | タンパク質徐放用の生物分解性ドラッグデリバリーシステム |
| EP2916827B1 (en) | 2012-11-08 | 2020-06-10 | Clearside Biomedical Inc. | Methods for the treatment of ocular disease in human subjects |
| CN102988301A (zh) * | 2012-12-26 | 2013-03-27 | 温州医学院 | 一种含贝伐单抗的长效缓释微球的制备方法 |
| EP2968113B8 (en) | 2013-03-14 | 2020-10-28 | Forsight Vision4, Inc. | Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant |
| CN104884133B (zh) | 2013-03-14 | 2018-02-23 | 艾肯运动与健康公司 | 具有飞轮的力量训练设备 |
| SG11201509051VA (en) | 2013-05-03 | 2015-12-30 | Clearside Biomedical Inc | Apparatus and methods for ocular injection |
| WO2014197317A1 (en) | 2013-06-03 | 2014-12-11 | Clearside Biomedical, Inc. | Apparatus and methods for drug delivery using multiple reservoirs |
| US20160166701A1 (en) * | 2013-07-05 | 2016-06-16 | Therakine Biodelivery Gmbh | Delivery composition for topical applications and injections and ophthalmic formulations, methods for manufacturing thereof, and methods for delivery of a drug-delivery composition |
| US9782345B2 (en) | 2013-10-17 | 2017-10-10 | Jade Therapeutics, Inc. | Ocular composition and method |
| US10568951B2 (en) | 2013-11-18 | 2020-02-25 | Formycon Ag | Pharmaceutical composition of an anti-VEGF antibody |
| US9403047B2 (en) | 2013-12-26 | 2016-08-02 | Icon Health & Fitness, Inc. | Magnetic resistance mechanism in a cable machine |
| CN106470739B (zh) | 2014-06-09 | 2019-06-21 | 爱康保健健身有限公司 | 并入跑步机的缆索系统 |
| CA2952958A1 (en) | 2014-06-20 | 2015-12-23 | Clearside Biomedical, Inc. | Variable diameter cannula and methods for controlling insertion depth for medicament delivery |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| BR112017002466A2 (pt) | 2014-08-08 | 2017-12-05 | Forsight Vision4 Inc | formulações estáveis e solúveis de inibidores da tirosina cinase do receptor, e métodos para a sua preparação |
| USD750223S1 (en) | 2014-10-14 | 2016-02-23 | Clearside Biomedical, Inc. | Medical injector for ocular injection |
| EP3261630A4 (en) * | 2015-02-26 | 2018-10-10 | Feramda Ltd. | Compositions and combinations for the treatment of angiogenesis diseases and disorders |
| ES2584534B1 (es) * | 2015-03-27 | 2017-03-13 | Retinset, S.L. | Formulación tópica oftálmica de bosentan |
| KR101846306B1 (ko) | 2015-03-31 | 2018-05-18 | 일동제약(주) | 조직투과성 펩타이드와 항-혈관 내피세포 성장인자 제제가 융합된 융합단백질을 유효성분으로 포함하는 안질환 예방 및 치료용 약학적 조성물 |
| CN113786489A (zh) * | 2015-05-29 | 2021-12-14 | 生化学工业株式会社 | 包含糖胺聚糖衍生物和趋化因子受体活性调节材料的组合物 |
| US10953305B2 (en) | 2015-08-26 | 2021-03-23 | Icon Health & Fitness, Inc. | Strength exercise mechanisms |
| US10940360B2 (en) | 2015-08-26 | 2021-03-09 | Icon Health & Fitness, Inc. | Strength exercise mechanisms |
| TWI799366B (zh) | 2015-09-15 | 2023-04-21 | 美商建南德克公司 | 胱胺酸結骨架平臺 |
| IL257565B1 (en) | 2015-09-23 | 2024-04-01 | Genentech Inc | Improved variants of anti-VEGF antibodies |
| KR20180104635A (ko) | 2015-12-30 | 2018-09-21 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| IL295558A (en) * | 2016-02-08 | 2022-10-01 | Univ Johns Hopkins | Hydrogel polymer bioadhesive-dendrimer nanoadhesive and its use |
| WO2017139375A1 (en) | 2016-02-10 | 2017-08-17 | Clearside Biomedical, Inc. | Ocular injection kit, packaging, and methods of use |
| CN109073660B (zh) * | 2016-02-29 | 2022-10-28 | 麦恩泰科特有限公司 | 可用于治疗湿性年龄相关性黄斑变性的预测性标志物 |
| JP6664115B2 (ja) * | 2016-03-15 | 2020-03-13 | 原 英彰 | アフリベルセプトによる網膜保護作用 |
| US10293211B2 (en) | 2016-03-18 | 2019-05-21 | Icon Health & Fitness, Inc. | Coordinated weight selection |
| US10441840B2 (en) | 2016-03-18 | 2019-10-15 | Icon Health & Fitness, Inc. | Collapsible strength exercise machine |
| JP2019514581A (ja) | 2016-05-02 | 2019-06-06 | クリアサイド バイオメディカル，インコーポレイテッド | 眼の薬物送達のためのシステムおよび方法 |
| US10252109B2 (en) | 2016-05-13 | 2019-04-09 | Icon Health & Fitness, Inc. | Weight platform treadmill |
| ES2886542T3 (es) | 2016-05-25 | 2021-12-20 | Santen Pharmaceutical Co Ltd | Uso de sirolimus para tratar la degeneración macular asociada con la edad exudativa con edema persistente |
| CN110177527B (zh) | 2016-08-12 | 2022-02-01 | 科尼尔赛德生物医学公司 | 用于调节药剂递送用针的插入深度的装置和方法 |
| US10661114B2 (en) | 2016-11-01 | 2020-05-26 | Icon Health & Fitness, Inc. | Body weight lift mechanism on treadmill |
| US11123411B2 (en) * | 2016-12-08 | 2021-09-21 | Gary E. Borodic | Method of treating macular degeneration using botulinum toxin-based pharmaceuticals |
| RU2661621C2 (ru) * | 2016-12-19 | 2018-07-17 | Александр Николаевич Епихин | Способ пролонгации и усиления терапевтического эффекта действия ингибиторов ангиогенеза при лечении неоваскулярных форм макулярных дегенераций |
| CA3055985A1 (en) | 2017-03-22 | 2018-09-27 | Genentech, Inc. | Hydrogel cross-linked hyaluronic acid prodrug compositions and methods |
| AU2018258654B2 (en) | 2017-04-27 | 2022-01-06 | The Johns Hopkins University | Dendrimer compositions for use in angiography |
| KR102101969B1 (ko) * | 2017-09-06 | 2020-04-22 | (주)인벤티지랩 | 목시덱틴을 포함하는 마이크로 입자 및 이의 제조 방법 |
| US11918657B2 (en) | 2017-11-10 | 2024-03-05 | The Johns Hopkins University | Dendrimer delivery system and methods of use thereof |
| CN115607358A (zh) | 2017-11-21 | 2023-01-17 | 弗赛特影像4股份有限公司 | 用于可扩展端口递送系统的流体交换装置及使用方法 |
| CN108030783A (zh) * | 2017-12-27 | 2018-05-15 | 广东众生药业股份有限公司 | 乐伐替尼在制备防治黄斑变性的药物中的用途 |
| SG11202010178XA (en) * | 2018-04-17 | 2020-11-27 | Outlook Therapeutics Inc | Buffered formulations of bevacizumab for use of treating diseases |
| KR102192768B1 (ko) * | 2018-12-07 | 2020-12-18 | 전북대학교산학협력단 | 식나무 추출물을 포함하는 황반변성의 예방 또는 치료용 약학적 조성물 |
| DE102019112917B4 (de) * | 2019-05-16 | 2021-07-22 | Carl Zeiss Meditec Ag | Ophthalmologisches Implantat zur Verwendung bei der Behandlung einer Augenkrankheit und Implantationswerkzeug mit einem solchen ophthalmologischen Implantat |
| CN109966243A (zh) * | 2019-05-17 | 2019-07-05 | 上海第二工业大学 | 一种用于眼底黄斑治疗的释药型凝胶及其制备方法 |
| US11141425B2 (en) * | 2019-06-27 | 2021-10-12 | University Of Florida Research Foundation, Incorporated | Enhancing AAV-mediated transduction of ocular tissues with hyaluronic acid |
| CN114340690B (zh) | 2019-06-27 | 2023-11-03 | 雷尔生物公司 | 眼部装置递送方法和系统 |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| IL295357A (en) | 2020-02-06 | 2022-10-01 | Ocular Therapeutix Inc | Preparations and methods for the treatment of eye diseases |
| PL3884929T3 (pl) | 2020-03-25 | 2023-10-09 | Ocular Therapeutix, Inc. | Wprowadzany do oka wszczep zawierający inhibitor kinazy tyrozynowej |
| EP4277640A1 (en) * | 2021-01-12 | 2023-11-22 | The Regents Of The University Of Michigan | Treatment and prevention of dry macular degeneration |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2446405A (en) | 1945-10-31 | 1948-08-03 | Hazeltine Research Inc | Tunable ultra high frequency resonator system |
| US5164188A (en) | 1989-11-22 | 1992-11-17 | Visionex, Inc. | Biodegradable ocular implants |
| KR0185215B1 (ko) | 1990-11-30 | 1999-05-01 | 요시다 쇼오지 | 서방성 안구삽입용 약제 |
| US5264188A (en) * | 1991-01-22 | 1993-11-23 | Phillips Petroleum Company | Multi-stage hydrotreating process and apparatus |
| US5869079A (en) * | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
| EP1156820B1 (en) * | 1999-02-08 | 2008-07-09 | Human Genome Sciences, Inc. | Use of vascular endothelial growth factor-2 (vegf-2) |
| US7582311B1 (en) * | 1999-10-15 | 2009-09-01 | Genentech, Inc. | Injection vehicle for polymer-based formulations |
| CA2383572C (en) * | 1999-10-21 | 2007-12-11 | Alcon Universal Ltd. | Sub-tenon drug delivery |
| US20040229960A1 (en) | 2001-07-13 | 2004-11-18 | David Sherris | Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases |
| RU2354398C2 (ru) * | 2001-07-13 | 2009-05-10 | Оксиджин, Инк. | Композиции и способы введения средств, связывающих тубулин, для лечения глазных заболеваний |
| PL223153B1 (pl) * | 2002-09-18 | 2016-10-31 | Allergan Inc | Urządzenie do wszczepiania implantu okulistycznego |
| EP1562597A4 (en) * | 2002-10-31 | 2008-05-14 | Celgene Corp | COMPOSITIONS COMPRISING IMMUNOMODULATORY COMPOUNDS FOR THE TREATMENT AND MANAGEMENT OF MACULAR DEGENERATION AND METHODS OF USE THEREOF |
| US20050250737A1 (en) * | 2003-11-12 | 2005-11-10 | Allergan, Inc. | Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods |
| US20050101582A1 (en) | 2003-11-12 | 2005-05-12 | Allergan, Inc. | Compositions and methods for treating a posterior segment of an eye |
| US8722097B2 (en) * | 2004-04-30 | 2014-05-13 | Allergan, Inc. | Oil-in-water method for making polymeric implants containing a hypotensive lipid |
| US7589057B2 (en) * | 2004-04-30 | 2009-09-15 | Allergan, Inc. | Oil-in-water method for making alpha-2 agonist polymeric drug delivery systems |
| US7799336B2 (en) * | 2004-04-30 | 2010-09-21 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
| US8591885B2 (en) | 2004-04-30 | 2013-11-26 | Allergan, Inc. | Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems |
| US7993634B2 (en) * | 2004-04-30 | 2011-08-09 | Allergan, Inc. | Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods |
| US8425929B2 (en) * | 2004-04-30 | 2013-04-23 | Allergan, Inc. | Sustained release intraocular implants and methods for preventing retinal dysfunction |
| US20060182781A1 (en) * | 2004-04-30 | 2006-08-17 | Allergan, Inc. | Methods for treating ocular conditions with cyclic lipid contraining microparticles |
| US20070059336A1 (en) | 2004-04-30 | 2007-03-15 | Allergan, Inc. | Anti-angiogenic sustained release intraocular implants and related methods |
| US20050244469A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
| US20050244472A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Intraocular drug delivery systems containing excipients with reduced toxicity and related methods |
| US20050244471A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Estradiol derivative and estratopone containing sustained release intraocular implants and related methods |
| US20050244463A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular vasculopathies |
| US20060182783A1 (en) * | 2004-04-30 | 2006-08-17 | Allergan, Inc. | Sustained release intraocular drug delivery systems |
| WO2006086750A1 (en) * | 2005-02-09 | 2006-08-17 | Macusight, Inc. | Liquid formulations for treatment of diseases or conditions |
| CN101180086A (zh) * | 2005-04-08 | 2008-05-14 | 苏尔莫迪克斯公司 | 用于经视网膜下递送的持续释放植入物 |
| TWI370137B (en) * | 2005-09-07 | 2012-08-11 | Amgen Fremont Inc | Human monoclonal antibodies to activin receptor-like kinase-1 |
| US8168584B2 (en) * | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
| US8877229B2 (en) * | 2005-12-02 | 2014-11-04 | Eyetech Inc. | Controlled release microparticles |
| US20090221684A1 (en) * | 2005-12-22 | 2009-09-03 | Trustees Of Boston University | Molecules for Gene Delivery and Gene Therapy, and Methods of Use Thereof |
| CA2640151A1 (en) * | 2006-01-26 | 2007-08-09 | Acucela, Inc. | Compositions and methods for treatment of ophthalmic diseases and disorders |
| AU2007247426B2 (en) | 2006-05-04 | 2012-03-08 | Fondation Ophthalmologique Adolf De Rothschild | Combination comprising a VEGF inhibitor and a serine protease for treating neovascular diseases |
| JP2010502603A (ja) * | 2006-08-31 | 2010-01-28 | アブラクシス バイオサイエンス， エルエルシー | 血管形成を阻害し、血管形成関連疾患を処置する方法 |
| CA2666709A1 (en) | 2006-11-10 | 2008-05-29 | Genentech, Inc. | Method for treating age-related macular degeneration |
| CA2670418A1 (en) * | 2006-11-24 | 2008-05-29 | Ac Immune Sa | N-(methyl)-1h-pyrazol-3-amine, n-(methyl)-pyridin-2-amine and n-(methyl)-thiazol-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimers's |
| US20080125377A1 (en) * | 2006-11-28 | 2008-05-29 | Bartels Stephen P | Delivery system for antiangiogenic and antiinflammatory pharmaceuticals and method of use |
| US8969415B2 (en) * | 2006-12-01 | 2015-03-03 | Allergan, Inc. | Intraocular drug delivery systems |
| US11078262B2 (en) * | 2007-04-30 | 2021-08-03 | Allergan, Inc. | High viscosity macromolecular compositions for treating ocular conditions |
| US8821870B2 (en) * | 2008-07-18 | 2014-09-02 | Allergan, Inc. | Method for treating atrophic age related macular degeneration |
| CA2968112A1 (en) | 2016-05-26 | 2017-11-26 | Op-Hygiene Ip Gmbh | Dispenser servicing in a multiple washroom facility |
| US11935002B2 (en) | 2019-05-23 | 2024-03-19 | Capital One Services, Llc | Multi-lender platform that securely stores proprietary information for generating offers |
-
2008
- 2008-07-18 US US12/176,238 patent/US8821870B2/en active Active
-
2009
- 2009-07-13 JP JP2011518816A patent/JP2011528656A/ja active Pending
- 2009-07-13 CN CN201611271046.2A patent/CN107412778A/zh active Pending
- 2009-07-13 EP EP19161922.0A patent/EP3524270B1/en active Active
- 2009-07-13 ES ES13179231T patent/ES2720882T3/es active Active
- 2009-07-13 EP EP21196540.5A patent/EP3950002A1/en not_active Withdrawn
- 2009-07-13 RU RU2011105409/15A patent/RU2521338C9/ru active
- 2009-07-13 CN CN2009801368268A patent/CN102159246A/zh active Pending
- 2009-07-13 ES ES09790328.0T patent/ES2574706T3/es active Active
- 2009-07-13 BR BRPI0915981-9A patent/BRPI0915981A2/pt not_active Application Discontinuation
- 2009-07-13 AU AU2009271168A patent/AU2009271168B2/en not_active Ceased
- 2009-07-13 EP EP09790328.0A patent/EP2307055B1/en active Active
- 2009-07-13 ES ES19161922T patent/ES2897560T3/es active Active
- 2009-07-13 KR KR1020117003673A patent/KR20110047196A/ko active Search and Examination
- 2009-07-13 CA CA2731270A patent/CA2731270C/en not_active Expired - Fee Related
- 2009-07-13 WO PCT/US2009/050373 patent/WO2010009034A2/en active Application Filing
- 2009-07-13 EP EP13179231.9A patent/EP2664347B1/en active Active
- 2009-07-13 RU RU2014115647A patent/RU2668371C2/ru active
-
2014
- 2014-07-07 US US14/324,630 patent/US10363214B2/en active Active
- 2014-08-22 JP JP2014169846A patent/JP6009511B2/ja not_active Expired - Fee Related
-
2016
- 2016-06-23 JP JP2016124732A patent/JP6132964B2/ja not_active Expired - Fee Related
-
2018
- 2018-09-19 RU RU2018133133A patent/RU2018133133A/ru not_active Application Discontinuation
-
2019
- 2019-07-19 US US16/516,411 patent/US20190336441A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2014115647A (ru) | Способ лечения атрофической возрастной макулярной дегенерации | |
| Kornev et al. | Hydrogel-assisted neuroregeneration approaches towards brain injury therapy: A state-of-the-art review | |
| Shirzaei Sani et al. | Engineering adhesive and antimicrobial hyaluronic acid/elastin-like polypeptide hybrid hydrogels for tissue engineering applications | |
| CN101658491B (zh) | 一种治疗角膜碱烧伤的羊膜滴眼液 | |
| Hong et al. | Injectable polypeptide thermogel as a tissue engineering system for hepatogenic differentiation of tonsil-derived mesenchymal stem cells | |
| Yu et al. | In situ covalently cross-linked PEG hydrogel for ocular drug delivery applications | |
| US20100285094A1 (en) | Polymeric compositions and methods of making and using thereof | |
| CA2662209C (en) | Implantable devices for producing insulin | |
| Mazumder et al. | Cell‐adhesive thermogelling PNIPAAm/hyaluronic acid cell delivery hydrogels for potential application as minimally invasive retinal therapeutics | |
| Zustiak et al. | Hydrolytically degradable poly (ethylene glycol) hydrogel scaffolds as a cell delivery vehicle: characterization of PC12 cell response | |
| KR20200130685A (ko) | 가교된 히알루론산 및 prp/bmc와의 조합물 | |
| CY1109425T1 (el) | Φαρμακευτικες συνθεσεις για τη χορηγηση με ελεγχομενη αποδεσμευση βιολογικα δραστικων ενωσεων | |
| EP2498824A2 (en) | Hydrogels based on polymers of dextran tyramine and tyramine conjugates of natural polymers | |
| US20130129797A1 (en) | Polymeric compositions and methods of making and using thereof | |
| US20150337121A1 (en) | Multifunctional tunable biomaterials for tissue engineering | |
| EP3534886A1 (en) | Hydrogen sulfide releasing polymer compounds | |
| Park et al. | An anti‐angiogenic reverse thermal gel as a drug‐delivery system for age‐related wet macular degeneration | |
| Ding et al. | Injectable in situ forming double-network hydrogel to enhance transplanted cell viability and retention | |
| Martin et al. | Oxidation‐responsive, tunable growth factor delivery from polyelectrolyte‐coated implants | |
| Noverraz et al. | Antifibrotic effect of ketoprofen-grafted alginate microcapsules in the transplantation of insulin producing cells | |
| KR20180104646A (ko) | 면역관용 반응을 구축하기 위한 조성물 및 방법 | |
| Mi et al. | Fabrication of chondroitin sulfate‐chitosan composite artificial extracellular matrix for stabilization of fibroblast growth factor | |
| WO2013107092A1 (zh) | 一种水凝胶及其制备方法 | |
| Kim et al. | Injectable hydrogel based on gellan gum/silk sericin for application as a retinal pigment epithelium cell carrier | |
| KR100776297B1 (ko) | 주사형 광가교 수화젤, 이를 이용한 생분해성 이식조직,주사형 약물전달 제제 및 이의 제조방법 |